Clinical Trial Detail

NCT ID NCT02379247
Title BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors University of Kansas
Indications

Her2-receptor negative breast cancer

Therapies

Alpelisib + Nab-paclitaxel

Age Groups: adult

Additional content available in CKB BOOST